Interestingly, using a human iPS cells-derived model of Parkinson’s disease, it was found that the myocyte enhancer factor 2C-peroxisome proliferator-activated receptor-γ coactivator-1α (MEF2C-PGC1α) pathway may be a new therapeutic target for Parkinson’s disease. Here, MEF2C is linked to Parkinson disease.